Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Allergen immunotherapy (9)
  • x Asthma (20)
  • Basic immunology (3)
  • Biologicals (7)
  • Biomarkers (3)
  • COVID19 (1)
  • ENT (2)
  • Environmental allergy and climate change (1)
  • Eosinophilic esophagitis (1)
  • Epidemiology (1)
  • Immune deficiencies and autoimmunity (2)
  • Infections (3)
  • Mastocytosis and mast cells (1)
  • Microbiome (1)
  • Occupational allergy (2)
  • Ocular allergy (1)
  • Pediatrics (11)
Poster available until
Poster categories
  • Thematic Poster Session (4)
keywords
Session Reference
  • L-TPS02 (14)
  • L-TPS09 (6)
  • L-TPS10 (12)
  • L-TPS16 (14)
  • L-TPS18 (2)
  • L-TPS19 (1)
  • TPS06 (9)
  • TPS07 (11)
  • TPS08 (1)
  • x TPS09 (4)
  • TPS19 (1)
  • TPS25 (1)
  • TPS28 (1)
  • TPS29 (15)
  • TPS30 (11)
  • TPS31 (15)
  • TPS51 (9)
  • TPS55 (13)
  • x TPS56 (16)
  • TPS57 (12)
  • TPS69 (1)
20 results
Thumbnail

D1.149 - Murine IgG1 increased y subcutaneous immunotherapy suppressed development of allergic asthma

Thumbnail

D1.150 - Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)

Thumbnail

D1.153 - Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites

Thumbnail

D1.154 - Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix

Thumbnail

- D3.114 - Does severe asthma exist in preschool children?

Thumbnail

- D3.115 - Outcome and complications of COVID-19 among children with asthma in South Korea: a national incident cohort study

Thumbnail

- D3.116 - Mepolizumab as game changer in a case of severe occupational asthma with rhinitis and contact dermatitis

Thumbnail

- D3.117 - Targeting Mast Cells with Briquilimab, an Anti-Human c-Kit (CD117) Antibody, Mitigates COPD-Like Features in an Allergen and Cigarette Smoke-Exacerbated Asthma Model Using Humanized h/mCD117 Mice

Thumbnail

- D3.118 - Antibiotic Cocktail-Induced Gut Microbiota Dysbiosis Modulates Gut and Airway Immunity, Attenuating Allergic Airway Inflammation

Thumbnail

- D3.119 - Selection of Biologics for Severe Pediatric Asthma with Allergic Eosinophilic Phenotype

Thumbnail

- D3.122 - Management Challenges in Pediatric Asthma with Long QT Syndrome

Thumbnail

- D3.123 - Dupilumab: Improved Asthma Control and Quality of Life in Pediatric Patients - A Real-World, Single-Center Study

Thumbnail

- D3.124 - Severe asthma associated with hereditary angioedema type 1 and other pathologies

Thumbnail

- D3.125 - ‘’Save the World-SynAir-G": Evaluation of Internal Reliability of an Innovative Application for Student Health Data Collection

Thumbnail

- D3.126 - Occupational exposure, sensitisation and respiratory symptoms in shrimp processing plants

Thumbnail

- D3.127 - A cost effective, self-sustaining, and effective way of improving asthma understanding in undergraduate students

Thumbnail

- D3.128 - THE BACK COVER OF ASTHMA: Retrospective case-report of a 21-year-old woman

Thumbnail

- D3.129 - Descriptive Analysis of Health-Related Physical Activity Patterns Among Korean Adolescents Diagnosed with Asthma

Thumbnail

- D3.130 - Selective IgA Deficiency in the Pediatric Population: A Gateway to Allergies and Autoimmunity

Thumbnail

- D3.131 - Predictors of Asthma Development Following Rhinovirus Infection in Preschool Children

Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM